γδ T cells in cancer immunotherapy: Current status and future prospects

Immunotherapy

Volumn 1, Issue 4, 2009, Pages 663-678

  Chiplunkar, Shubhada ^a   Dhar, Swati ^a   Wesch, Daniela ^b   Kabelitz, Dieter ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

T cell; Aminobisphosphonate; Clinical trial; Dendritic cell; Phosphoantigen; Receptor; Regulatory T cell; Toll like receptor; Tumor immunotherapy

Indexed keywords

ALENDRONIC ACID; ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; CLODRONIC ACID; CYTOKINE; ETIDRONIC ACID; HYBRID PROTEIN; IBANDRONIC ACID; IMATINIB; MINODRONIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU 14.18; PAMIDRONIC ACID; PHOSPHOANTIGEN; PHOSPHOSTIM; PICOSTIM; PROTEIN FC IL7; RECOMBINANT INTERLEUKIN 2; RISEDRONIC ACID; RITUXIMAB; TILUDRONIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL MIGRATION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DENDRITIC CELL; DRUG DOSE INCREASE; DRUG MECHANISM; EFFECTOR CELL; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR LOCALIZATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CELL COMMUNICATION; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; IMMUNOLOGY; NEOPLASM; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL COMMUNICATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; DRUG COMBINATIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77953375569     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.27     Document Type: Review

References (121)

1. Holtmeier W, Chowers Y, Lumeng A, Morzycka-Wroblewska E, Kagnoff MF: The δ T cell receptor repertoire in human colon and peripheral blood is oligoclonal irrespective of V region usage. J. Clin. Invest. 96, 1108-1117 (1995).
2. Tanaka Y, Sano S, Nieves E et al.: Nonpeptide ligands for human γδ T cells. Proc. Natl Acad. Sci. USA 91, 8175-8179 (1994). •• Seminal study reporting the nature of phosphoantigens activating Vγ9Vδ2 T cells.
3. Feurle J, Espinosa E, Eckstein S et al.: Escherichia coli produces phosphoantigens activating human γδ T cells. J. Biol. Chem. 277, 148-154 (2002). (Pubitemid 34952039)
4. Poccia F, Battistini L, Cipriani B et al.: Phosphoantigen-reactive Vγ9Vδ2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J. Infect. Dis. 180, 858-861 (1999).
5. Poccia F, Agrati C, Castilletti C et al.: Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by Vγ9Vδ2 T cells. J. Infect. Dis. 193, 1244-1249 (2006).
6. Agrati C, Alonzi T, de Santis R et al.: Activation of Vγ9Vδ2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. Int. Immunol. 18, 11-18 (2006).
7. Martino A, Poccia F: γδ T cells and dendritic cells: close partners and biological adjuvants for new therapies. Curr. Mol. Med. 7, 658-673 (2007).
8. Kabelitz D: Small molecules for the activation of human γδ T cell responses against infection. Recent Patents Anti-Infect. Drug Disc. 3, 1-9 (2008).
9. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96, 384-392 (2000).
10. Bukowski JF, Morita CT, Brenner MB: Human γδ T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11, 57-65 (1999). • First report of alkylamines activating human γδ T cells.
11. Gober HJ, Kistowska M, Angman L et al.: G: Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163-168 (2003). •• Reports for the first time that human γδ T cells are activated by endogenous ligands of the mevalonate pathway.
12. Thompson K, Rojas-Navea J, Rogers MJ: Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107, 651-654 (2006). (Pubitemid 43076390)
13. Wei Y, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A: Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of γδ T cells and heat shock protein 70. Cancer Res. 56, 1104-1110 (1996).
14. Laad AD, Thomas ML, Fakih AR, Chiplunkar SV: Human γδ T cells recognize heat shock protein-60 on oral tumor cells. Int. J. Cancer 80, 709-714 (1999).
15. Thomas ML, Samant UC, Deshpande RK, Chiplunkar SV: γδ T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol. Immunother. 48, 653-659 (2000).
16. Hirsh MI, Hashiguchi N, Chen Y, Yip L, Junger WG: Surface expression of HSP72 by LPS-stimulated neutrophils facilitates γδT cell-mediated killing. Eur. J. Immunol. 36, 712-721 (2006).
17. Scotet E, Martinez LO, Grant E et al.: Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22, 71-80 (2005). •• Interesting study that shows the involvement of F1-ATPase, Apo-I and γδ T-cell receptors (TCR) as a trimolecular complex, thereby identifying a novel putative ligand for γδ T cells. (Pubitemid 40143452)
18. Girlanda S, Fortis C, Belloni D et al.: MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated γδ lymphocytes. Cancer Res. 65, 7502-7508 (2005). (Pubitemid 41161286)
19. Wrobel P, Shojaei H, Schittek B et al.: Lysis of a broad range of epithelial tumour cells by human γ δ T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand. J. Immunol. 66, 320-328 (2007). • Comprehensive study representing the broad antitumor activity of Vγ9Vδ2 T cells and its partial dependence on NKG2D.
20. Holtmeier W, Pfander M, Hennemann A, Zollner TM, Kaufmann R, Caspary WF: The TCR-δ repertoire in normal human skin is restricted and distinct from the TCR-δ repertoire in the peripheral blood. J. Invest. Dermatol. 116, 275-280 (2001). •• First study establishing that normal human skin harbors γδ T cells with a δ gene repertoire distinct from that of peripheral blood.
21. Ebert LM, Meuter S, Moser B: Homing and function of human skin γδ T cells and NK cells: relevance for tumor surveillance. J. Immunol. 176, 4331-4336 (2006).
22. Groh V, Steinle A, Bauer S, Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279, 1737-1740 (1998). •• Important study reporting for the first time the recognition of stress-induced molecules by intestinal γγ T cells. (Pubitemid 28164472)
23. Zhao J, Huang J, Chen H, Cui L, He W: Vδ1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem. Biophys. Res. Commun. 339, 232-240 (2006).
24. Spada FM, Grant EP, Peters PJ et al.: Self-recognition of CD1 by γ/δ T cells: implications for innate immunity. J. Exp. Med. 191, 937-948 (2000). •• Reports for the first time the recognition of CD1c by Vδ1 T cells.
25. Vincent MS, Roessner K, Sellati T et al.: Lyme arthritis synovial γ δ T cells respond to Borrelia buryδorferi lipoproteins and lipidated hexapeptides. J. Immunol. 161, 5762-5771 (1998). (Pubitemid 28519145)
26. Collins C, Shi C, Russell JQ, Fortner KA, Budd RC: Activation of γ δ T cells by Borrelia burgdorferi is indirect via a TLR- and caspase-dependent pathway. J. Immunol. 181, 2392-2398 (2008). • The authors report an indirect mechanism by which the spirochete Borrelia burgdorferi induces monocytes to upregulate a putative ligand recognized by Vδ1 T cells via a Toll-like receptor (TLR)2 and caspase pathway.
27. Rust C, Orsini D, Kooy Y, Koning F: Reactivity of human γ δ T cells to staphylococcal enterotoxins: a restricted reaction pattern mediated by two distinct recognition pathways. Scand. J. Immunol. 38, 89-94 (1993).
28. + T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat. Immun. 14, 188-197 (1995).
29. Wilding EI, Brown JR, Bryant AP et al.: Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in Gram-positive cocci. J. Bacteriol. 182, 4319-4327 (2000).
30. Wilding EI, Kim DY, Bryant AP et al.: Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus. J. Bacteriol. 182, 5147-5152 (2000).
31. Poquet Y, Constant P, Halary F et al.: A novel nucleotide-containing antigen for human blood γ δ T lymphocytes. Eur. J. Immunol. 26, 2344-2349 (1996).
32. Tanaka Y, Kobayashi H, Terasaki T et al.: Synthesis of pyrophosphate-containing compounds that stimulate Vγ2Vδ2 T cells: application to cancer immunotherapy. Med. Chem. 3, 85-99 (2007).
33. Puan KJ, Jin C, Wang H et al.: Preferential recognition of a microbial metabolite by human Vγ2Vδ2 T cells. Int. Immunol. 19, 657-673 (2007).
34. Hintz M, Reichenberg A, Altincicek B et al.: Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett. 509, 317-322 (2001). • Establishes the stimulatory potential of 4-hydroxy-3-methyl-but-2-enyl (HMB-PP) on human γδ T cells. (Pubitemid 34015963)
35. Schoel B, Sprenger S, Kaufmann SH: Phosphate is essential for stimulation of V γ 9V δ 2 T lymphocytes by mycobacterial low molecular weight ligand. Eur. J. Immunol. 24, 1886-1892 (1994). • Initial study establishing that antigenicity of phosphoantigens is controlled by the crucial phosphate moiety.
36. Amslinger S, Hecht S, Rohdich F et al.: Stimulation of Vγ9/Vδ2 T-lymphocyte proliferation by the isoprenoid precursor, (E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate. Immunobiol. 212, 47-55 (2007). • Establishes the rationale of exploring derivatives of the 1-hydroxy-2-methyl-but-2-enyl 4-diphosphate pathway with increased stimulatory activity.
37. Sireci G, Espinosa E, Di Sano C, Dieli F, Fournie JJ, Salerno A: Differential activation of human γδ cells by nonpeptide phosphoantigens. Eur. J. Immunol. 31, 1628-1635 (2001).
38. Kistowska M, Rossy E, Sansano S et al.: Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γ δ cells. Eur. J. Immunol. 38, 2200-2209 (2008).
39. Wei H, Huang D, Lai X et al.: Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vγ2Vδ2 TCR. J. Immunol. 181, 4798-4806 (2008). •• First evidence of a stable association of phosphoantigen HMB-PP with an antigen-presenting cell (APC) surface and binding of this complex to the Vγ9Vδ2 tetramer.
40. Sarikonda G, Wang H, Puan KJ et al.: Photoaffinity antigens for human γδ T cells. J. Immunol. 181, 7738-7750 (2008). •• First study of its kind reporting a strategy of developing analogs of phosphoantigens that enables stable association of these antigens to APC surfaces. This would enable the study of putative receptors that bind to phosphoantigens.
41. Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 65, 4971-4974 (2005). (Pubitemid 40827299)
42. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108-111 (1999). • Elucidated for the first time that aminobisphosphonates inhibit a crucial enzyme of the cholesterol biosynthesis pathway.
43. Kavanagh KL, Guo K, Dunford JE et al.: The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl Acad. Sci. USA 103, 7829-7834 (2006).
44. Monkkonen H, Ottewell PD, Kuokkanen J, Monkkonen J, Auriola S, Holen I: Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci. 81, 1066-1070 (2007). • Reports induction of pro-apoptotic ATP analog (ApppI) in vivo in macrophages upon administration of zoledronic acid in mice. (Pubitemid 47418845)
45. Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12, 6222s-6230s (2006).
46. Berenson JR, Lipton A: Use of bisphosphonates in patients with metastatic bone disease. Oncology (Williston Park) 12, 1573-1579; discussion 1579-1581 (1998).
47. Rosen LS, Gordon D, Tchekmedyian S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150-3157 (2003).
48. Kunzmann V, Bauer E, Wilhelm M: γ/δ T-cell stimulation by pamidronate. N. Engl. J. Med. 340, 737-738 (1999). • First study showing the clinical relevance of pamidronate acting as an antigen responsible for expansion of human γδ T cells.
49. Kabelitz D, Wesch D, Pitters E, Zöller M: Characterization of tumor reactivity of human Vγ9Vδ2 γ δ T cells in vitro and in SCID mice in vivo. J. Immunol. 173, 6767-6776 (2004). •• One of the initial preclinical studies where the efficacy of aminobisphosphonate-activated γδ T cells was evaluated in pancreatic carcinoma and melanoma xenografted mice. (Pubitemid 39541063)
50. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N: Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immunol. 167, 5092-5098 (2001).
51. Das H, Wang L, Kamath A, Bukowski JF: Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98, 1616-1618 (2001). • Important study establishing that the γδ T-cell receptor plays an important role in the recognition of aminobisphosphonates.
52. Corvaisier M, Moreau-Aubry A, Diez E et al.: V γ 9V δ 2 T cell response to colon carcinoma cells. J. Immunol. 175, 5481-5488 (2005). (Pubitemid 41456435)
53. Bouet-Toussaint F, Cabillic F, Toutirais O et al.: Vγ9Vδ2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol. Immunother. 57, 531-539 (2008).
54. Mattarollo SR, Kenna T, Nieda M, Nicol AJ: Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ 2 T cell cytotoxicity. Cancer Immunol. Immunother. 56, 1285-1297 (2007).
55. Guo BL, Liu Z, Aldrich WA, Lopez RD: Innate anti-breast cancer immunity of apoptosis-resistant human γδ-T cells. Breast Cancer Res. Treat. 93, 169-175 (2005).
56. Leslie DS, Vincent MS, Spada FM et al.: CD1-mediated γ/δ T cell maturation of dendritic cells. J. Exp. Med. 196, 1575-1584 (2002).
57. Conti L, Casetti R, Cardone M et al.: Reciprocal activating interaction between dendritic cells and pamidronate-stimulated γδ T cells: role of CD86 and inflammatory cytokines. J. Immunol. 174, 252-260 (2005). •• First evidence of reciprocal cross-talk between aminobisphosphonate-.stimulated γδ T cells and dendritic cells. (Pubitemid 40007411)
58. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E: Potentiation of antigen-stimulated V γ 9V δ 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J. Immunol. 176, 1386-1393 (2006). (Pubitemid 43134280)
59. Saito A, Narita M, Yokoyama A et al.: Enhancement of anti-tumor cytotoxicity of expanded γδ T cells by stimulation with monocyte-derived dendritic cells. J. Clin. Exp. Hematop. 47, 61-72 (2007).
60. Fiore F, Castella B, Nuschak B et al.: Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 110, 921-927 (2007). • Shows the capacity of zoledronate-stimulated immature/mature DCs in stimulating γδ T cells and cross-activating αβ T-cell responses. (Pubitemid 47267430)
61. Kunzmann V, Kretzschmar E, Herrmann T, Wilhelm M: Polyinosinic- polycytidylic acid-mediated stimulation of human γδ T cells via CD11c dendritic cell-derived type I interferons. Immunology 112, 369-377 (2004).
62. Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D: Direct costimulatory effect of TLR3 ligand poly(I:C) on human γδ T lymphocytes. J. Immunol. 176, 1348-1354 (2006). •• Direct costimulatory effect of TLR3 ligand polyinosinic-polycytidylic acid (Poly[I:C]) on human γδ T cells was demonstrated in this study.
63. Deetz CO, Hebbeler AM, Propp NA, Cairo C, Tikhonov I, Pauza CD: γ interferon secretion by human Vγ2Vδ2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-like receptor 2 agonist Pam3Cys. Infect. Immun. 74, 4505-4511 (2006). • Revealed a γδ T cell costimulatory pathway via TLR2.
64. Brandes M, Willimann K, Moser B: Professional antigen-presentation function by human γδ T cells. Science 309, 264-268 (2005). •• Established the antigen-presenting properties of activated human γδ T cells.
65. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
66. + regulatory T cells. Immunology 126, 256-267 (2009). • First study showing inhibitory effects of human Tregs on γδ T-cell activation.
67. + T regulatory cells in mycobacterial infection. Blood 113, 837-845 (2009). • Recent study reporting that inhibitory effects of Tregs on γδ T cells can be overcome by stimulation of γδ T cells with phosphoantigens.
68. + resting regulatory T cells from activated T cells. J. Immunol. 176, 2808-2816 (2006). (Pubitemid 43306940)
69. Latchman YE, Liang SC, Wu Y et al.: PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691-10696 (2004).
70. + regulatory T cell function. Science 322, 271-275 (2008).
71. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF: Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 27, 334-348 (2007). •• Interesting perspective on the suppressive role of tumor-infiltrating Vδ1 T cells on α/β T cells and dendritic cells in breast carcinoma.
72. Jameson JM, Sharp LL, Witherden DA, Havran WL: Regulation of skin cell homeostasis by γ δ T cells. Front. Biosci. 9, 2640-2651 (2004).
73. + intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J. Clin. Invest. 118, 281-293 (2008).
74. Kabelitz D, Wesch D: Features and functions of γ δ T lymphocytes: focus on chemokines and their receptors. Crit. Rev. Immunol. 23, 339-370 (2003).
75. Zocchi MR, Poggi A: Role of γδ T lymphocytes in tumor defense. Front. Biosci. 9, 2588-2604 (2004).
76. Viey E, Lucas C, Romagné F, Escudier B, Chouaib S, Caignard A: Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vγ9Vδ2 T cells from renal cell carcinoma patients. J. Immunother. 31, 313-323 (2008).
77. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F: Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 154, 3932-3940 (1995).
78. + T-cell receptors. J. Natl Cancer Inst. 88, 436-441 (1996).
79. + lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med.183, 1681-1696 (1996).
80. Thomas ML, Badwe RA, Deshpande RK, Samant UC, Chiplunkar SV: Role of adhesion molecules in recruitment of Vδ1 T cells from the peripheral blood to the tumor tissue of esophageal cancer patients. Cancer Immunol. Immunother. 50, 218-225 (2001).
81. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T: Activation of V γ 9V δ 2 T cells by NKG2D. J. Immunol. 175, 2144-2151 (2005). • Shows that NKG2D can directly activate human γδ T cells.
82. Poccia F, Cipriani B, Vendetti S et al.: CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V γ 9V δ 2 T lymphocytes. J. Immunol. 159, 6009-6017 (1997). (Pubitemid 127471537)
83. von Lilienfeld-Toal M, Nattermann J, Feldmann G et al.: Activated γδ T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin. Exp. Immunol, 144, 528-533 (2006).
84. Baisch H: Relationship between cell kinetics and apoptotic effects in TNF-α and IFN-γ-treated human tumour cell lines. Eur. Cytokine Netw. 12, 604-613 (2001).
85. +γδ T cells in mediating antitumor effector functions.
86. Dieli F, Vermijlen D, Fulfaro F et al.: Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450-7457 (2007). •• Report of a clinical trial conducted on patients with hormone-refractory prostate cancer with zoledronate and IL-2. Establishes the feasibility of γδ T cell immunotherapy with aminobisphosphonates.
87. Tassone P, Tagliaferri P, Viscomi C et al.: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer 88, 1971-1978 (2003).
88. Clezardin P, Fournier P, Boissier S, Peyruchaud O: In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. 10, 173-180 (2003).
89. Mariani S, Muraro M, Pantaleoni F et al.: Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19, 664-670 (2005).
90. Sato K, Kimura S, Hgawa H et al.: Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116, 94-99 (2005).
91. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J: Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for δ2 γ/δ T cells. J. Immunother. 30, 370-377 (2007).
92. Theill LE, Boyle WJ, Penninger JM: RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795-823 (2002).
93. Bukowski JF, Dascher CC, Das H: Alternative bisphosphonate targets and mechanisms of action. Biochem. Biophys. Res. Commun. 328, 746-750 (2005). • First study exploring the antiosteoclastic activity of activated γδ T cells.
94. Zheng BJ, Chan KW, Im S et al.: Anti-tumor effects of human peripheral γδ T cells in a mouse tumor model. Int. J. Cancer 92, 421-425 (2001).
95. Lozupone F, Pende D, Burgio VL et al.: Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 64, 378-385 (2004).
96. Sicard H, Ingoure S, Luciani B et al.: In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175, 5471-5480 (2005). •• Established the efficacy of immunomanipulation of γδ T cells in vivo with BrHPP (Phosphostim) administration, and initiated the possibility of immunotherapy with γδ T cells.
97. Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD: Protective immunosurveillance and therapeutic antitumor activity of γδ T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180, 6044-6053 (2008).
98. Ali Z, Shao L, Halliday L et al.: Prolonged (E)-4-hydroxy-3-methyl-but-2- enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vγ2Vδ2 T cells in macaques. J. Immunol. 179, 8287-8296 (2007).
99. Wilhelm M, Kunzmann V, Eckstein S et al.: γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200-206 (2003).
100. Dieli F, Gebbia N, Poccia F et al.: Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102, 2310-2311 (2003).
101. Vermijlen D, Ellis P, Langford C et al.: Distinct cytokine-driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J. Immunol. 178, 4304-4314 (2007).
102. Kobayashi H, Tanaka Y, Yagi J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56, 469-476 (2007).
103. Salot S, Laplace C, Saiagh S et al.: Large scale expansion of Vγ9δ2 T lymphocytes: Innacell γδ® cell therapy product. J. Immunol. Methods 326, 63-75 (2007). • Novel technique of ex vivo expansion of γδ T cells with BrHPP for clinical application. (Pubitemid 47361198)
104. Bennouna J, Bompas E, Neidhardt EM et al.: Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57, 1599-1609 (2008).
105. Simoni D, Gebbia N, Invidiata FP et al.: Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a γδ-T lymphocytes-mediated activation mechanism. J. Med. Chem. 51, 6800-6807 (2008). • Establishes the synthesis of novel aminobisphosphonate derivatives for efficient expansion of human γδ T cells.
106. Li XC, Demirci G, Ferrari-Lacraz S et al.: IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7, 114-118 (2001).
107. Eberl M, Engel R, Beck E, Jomaa H: Differentiation of human γ-δ T cells towards distinct memory phenotypes. Cell. Immunol. 218, 1-6 (2002).
108. Schulz SM, Kohler G, Holscher C, Iwakura Y, Alber G: IL-17A is produced by Th17, γδ T cells and other CD4- lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int. Immunol. 20, 1129-1138 (2008). • Reports the involvement of Th17-like γδ T cells in bacterial clearance of Salmonella enteridis. Suggests a potential role of IL-17-secreting γδ T cells in determining the fate of antimicrobial immune responses.
109. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL: γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 20, 353-357 (2008).
110. Otto M, Barfield RC, Martin WJ et al.: Combination immunotherapy with clinical-scale enriched human γδ T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin. Cancer Res. 11, 8486-8491 (2005).
111. Tokuyama H, Hagi T, Mattarollo SR et al.: Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int. J. Cancer 122, 2526-2534 (2008). •• Establishes the beneficial effects of combining γδ T-cell immunotherapy with monoclonal antibody therapy. (Pubitemid 351590486)
112. Ferrarini M, Heltai S, Toninelli E, Sabbadini MG, Pellicciari C, Manfredi AA: Daudi lymphoma killing triggers the programmed death of cytotoxic Vγ9/Vδ2 T lymphocytes. J. Immunol. 154, 3704-3712 (1995). • One of the earliest studies identifying the induction of activation-induced cell death (AICD) in γδ T cells mediated by tumor cells.
113. Atre N, Thomas L, Mistry R, Pathak K, Chiplunkar S: Role of nitric oxide in heat shock protein induced apoptosis of γδT cells. Int. J. Cancer 119, 1368-1376 (2006). • Reports the mechanism of AICD in γδ T cells from patients with head and neck squamous cell carcinoma, via the nitric oxide pathway activated by tumor cells. (Pubitemid 44258813)
114. Cendron D, Ingoure S, Martino A et al.: A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates. Eur. J. Immunol. 37, 549-565 (2007).
115. Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int. J. Cancer 119, 2359-2365 (2006). • Reveals a mechanism of immune escape utilized by tumors via soluble MHC class I-related chain A.
116. Oppenheim DE, Roberts SJ, Clarke SL et al.: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6, 928-937 (2005).
117. Stockinger B, Barthlott T, Kassiotis G: The concept of space and competition in immune regulation. Immunology 111, 241-247 (2004). (Pubitemid 38365744)
118. Pendrys DG, Silverman SL: Osteonecrosis of the jaws and bisphosphonates. Curr. Osteoporo.s Rep. 6, 31-38 (2008).
119. Hoffmann TK, Dworacki G, Tsukihiro T et al.: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 8, 2553-2562 (2002).
120. Kulkarni DP, Wadia PP, Pradhan TN, Pathak AK, Chiplunkar SV: Mechanisms involved in the down-regulation of TCR ζ chain in tumor versus peripheral blood of oral cancer patients. Int. J. Cancer 124, 1605-1613 (2009).
121. Inman BA, Frigola X, Harris KJ et al.: Questionable relevance of γδ T lymphocytes in renal cell carcinoma. J. Immunol. 180, 3578-3584 (2008). • Retrospective follow-up study of renal cell carcinoma patients where the authors could not correlate a potential role of γδ T cells with the clinical course.